Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been given an average rating of “Hold” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $62.1667.

A number of analysts have commented on the company. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Supernus Pharmaceuticals Trading Up 2.7%

Supernus Pharmaceuticals stock opened at $45.66 on Wednesday. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -89.53, a PEG ratio of 0.95 and a beta of 0.55. The stock has a fifty day simple moving average of $49.03 and a two-hundred day simple moving average of $49.56. Supernus Pharmaceuticals has a 12 month low of $30.83 and a 12 month high of $59.68.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 7,250 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the transaction, the vice president directly owned 17,044 shares in the company, valued at $845,382.40. This trade represents a 29.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Frederick M. Hudson sold 5,369 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director owned 60,413 shares in the company, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 97,619 shares of company stock valued at $4,908,275. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp boosted its stake in shares of Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after buying an additional 31,668 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after buying an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Supernus Pharmaceuticals by 12.7% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock worth $72,007,000 after buying an additional 162,905 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after buying an additional 61,120 shares during the last quarter. Finally, Woodline Partners LP lifted its position in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.